Results: 78 patients with BCLC Early HCC were identified. There was no difference in the number of tumours or selleck chemical total dimensions between the two groups. Demographic and Clinical Characteristics of Patients Based on their Performance

Status   Good PS Poor PS p value (n = 61) (n = 17) Age (mean±SD, yr) 57.9 ± 6.7 57.9 ± 9 0.96 Male sex (%) 90% 88% 0.99 Ethnicity (n, Caucasian/Asian/Other) 46/10/5 16/1/0 0.29 Treatment (n, RFA/SR/OLT) 19/15/27 5/2/10 0.52 Cirrhosis (%) 92% 100% 0.58 Portal hypertension (%) 77% 94% 0.17 MELD (mean±SD) 11.0 ± 4.5 14.2 ± 8.6 0.13 CP score (mean±SD) 6.2 ± 1.3 7.8 ± 2.3 0.001 ASA score (1&2 vs 3&4,n) 41/20 5/12 0.005 INR (mean± SD) 1.27 ± 0.18 1.48 ± 0.34 0.005 Non-liver co-morbidities (%) 44.3% 41.2% 0.41 On multivariate analysis the only significant difference between the two groups was INR (p = 0.005). There was no difference in outcomes in terms of tumour recurrence (30% vs 13.3% p = 0.45) and overall survival (67.2% vs 64.7%, p = 0.85) between the two groups. Kaplan Meier survival curve and log rank test showed no significant difference (p = 0.83). Conclusion: These results suggest that patients with BCLC Early HCC and poor PS are more likely to have cirrhosis Ixazomib manufacturer complicated by portal hypertension and more severe liver disease. A greater proportion has LT as their initial curative treatment. Although, patient PS appears to impact on initial treatment selection, overall survival is comparable

between patients with poor and good PS. This data supports the current practice of treating all BCLC Early HCC patients with curative intent irrespective of their PS. JYC TAN, P CREST, S ROBERTS, W KEMP Alfred Hospital, Melbourne, Victoria, Australia. Background: Hepatocellular

carcinoma (HCC) has a significant morbidity and mortality accounting for 6800 disability adjusted life years (DALYs) and five-year survival of 15.5%. The overall health care costs associated with managing HCC 上海皓元医药股份有限公司 in Australia are unknown. Improved understanding of the cost of HCC management is important to accurately determine and target the necessary resources required for managing these patients. We therefore evaluated the cost of providing care for HCC patients managed at The Alfred, a tertiary health provider. Methods: We included all patients with HCC managed at the Alfred Hospital over a 29 month period between January 2011 and May 2013. Baseline characteristics of patients and various aspects of clinical care including investigations, surgical and radiological interventions were recorded. Patients were managed according to current AASLD guidelines. Procedural costs were estimated using the Medicare Benefits Schedule or hospital purchase cost where appropriate. We excluded patients who underwent liver transplantation and the cost of unscheduled hospital admissions unrelated to HCC interventions and non-HCC related cost were also excluded from the analysis.